1Robins SJ. Fibrates and conmnaryheart disease reduction in diabetes[ J]. Curt Opin Endocrinol Diabetes,2002,9:312 - 322.
2Cusi K. Cardiovascular risk management in type 2 diabetes:from clinical trials toclinical practice [ J ]. Endocrinologist,2001,11:474 -490.
3UK Prospective Diabetes Study (UKP-DS) Group. Intensive blood - glucosecontrol with sulphonylureas or insulin compared with conventional treatmentand risk complications in patients with type 2 diabetes( UKPDS 33 ) [ J]. Lancet, 1998, 352:837 - 853.
4Vlassara H. Recent progress in advanced glycation end products and diabetic complications [ J ]. Diabetes, 1997,46[ Supp1]2:S19 -25.
5Lyons TJ, Jenkins AJ. Glycation, oxidation and lipoxidation in the develovment of the complications of diabetes mellitus : a" carbonyl stress" hypothesis [ J ].Diabete Rev, 1997,5:365 - 391.
6Turner RC, Millns H, Nell HAW, et al.Risk factors for coronary artery diseasenon - insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study[ Jl. Br Med J, 1998,316 : 823- 828.
7Turner BC. The U. K. prospective diabetes study:a review[J]. Diabetes Care,1998, 21 [ suppl ] 3:35 -38.
8Klein R, Klein BEK. Relation of glycenile control to diabetic complications anhealth outcomes. Diabetes Care,1998,21[ Suppl] 3:39 -43.
9UK Prospective Diabetes Study Group.Tight blood pressure control and risk ofmacrovascular and microvascular complications in type 2 diabetes: UKPDS 38[J]. BMJ, 1998,317:703-713.
10American Diabetes Association. Treatment of hypertension in adults with diabetes[J]. Diabetes Care,2002,25:199 -201.
